Novo Slides as Amgen Update Fuels Obesity Drug Competition Fears
Novo Nordisk A/S shares slid as a US rival’s comments on an experimental obesity drug gave rise to concerns about potential new competition in the rapidly growing field.
Novo Nordisk A/S shares slid as a US rival’s comments on an experimental obesity drug gave rise to concerns about potential new competition in the rapidly growing field.
Gold steadied as traders turned their focus to a critical US jobs report that could shift expectations of when the Federal Reserve will cut interest rates.
Stocks advanced before the US jobs report as Apple Inc. fanned optimism about the earnings power of big tech companies. The yen climbed to a three-week high.
Oil headed for its biggest weekly decline since February on signs of easing geopolitical risks in the Middle East and weakening fuel markets.
Nomura Holdings Inc. and Mizuho Financial Group Inc. are facing more than $100 million of potential losses tied to a series of failed stock trades made by investment fund All Blue Capital.
{{ video.ContentPackages[0].ScheduleStartDateTime | fromNow }}
{{ currentStream.Desc }}